W
WAVEMAN · COMPANY
KNSA · Kiniksa Pharmaceuticals International, Plc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

KNSA

Kiniksa Pharmaceuticals International, plc
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001730430
FORM 144 · 3☆ WATCH
INSIDER NET · 180D
-$34.7M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
157
13F, latest reported quarter
REVENUE GROWTH
+60.1%
XBRL, annual
NET MARGIN
8.7%
CONVERSIONS · 180D
53
codes C/M, not in net · $9.3M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$34.7M over 180 days
-$668.5K over 90 days
below 93% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
157 funds added or opened last quarter
more than 80% of Pharma & Biotech
REVENUE
+60.1% year over year
more than 81% of Pharma & Biotech
MARGIN
8.7% net margin
more than 79% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
5.0 days to cover · settled 2026-07-31
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$34.7M across 6 people in 180 days.
157 funds added or opened positions in the latest 13F quarter, of 268 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +127.3%
+127.3%12M
+0%+45%+91%+136%2025-092025-102025-122026-032026-052026-072026-09 2026-04-28 · Patel Sanj K sold $12.7M2026-04-28 · Patel Sanj K sold $5.9M2025-10-20 · Patel Sanj K sold $3.8M2025-10-22 · Patel Sanj K sold $3.8M2026-04-28 · Patel Sanj K sold $3.8M2025-10-31 · Paolini John F. sold $3.1M2025-09-04 · Tessari Eben sold $3.0M2026-04-28 · Patel Sanj K sold $2.8M2026-05-01 · Patel Sanj K sold $2.6M2026-05-01 · Paolini John F. sold $2.0M2025-12-08 · Ragosa Mark sold $1.8M2025-09-29 · Tessari Eben sold $1.6M2025-10-21 · Patel Sanj K sold $1.5M2025-10-20 · Megna Michael R sold $1.4M2026-04-29 · Patel Sanj K sold $1.2M2026-05-01 · Paolini John F. sold $1.1M2026-03-02 · Paolini John F. sold $997.4K2025-10-20 · Patel Sanj K sold $877.4K2026-03-09 · Ragosa Mark sold $866.6K2025-12-15 · Quart Barry D sold $835.6K2026-03-09 · Ragosa Mark sold $819.6K2025-11-12 · Ragosa Mark sold $814.7K2026-04-28 · Quart Barry D sold $656.3K2025-09-15 · Tessari Eben sold $584.8K2026-02-03 · Quart Barry D sold $567.1K2025-09-03 · Tessari Eben sold $535.7K2026-03-02 · Paolini John F. sold $533.2K2025-10-20 · Megna Michael R sold $520.3K2026-01-08 · Ragosa Mark sold $502.7K2025-12-15 · Tessari Eben sold $500.7K2025-11-17 · Tessari Eben sold $488.4K2025-09-05 · Tessari Eben sold $477.5K2025-10-14 · Tessari Eben sold $444.8K2026-02-09 · Ragosa Mark sold $390.5K2025-09-03 · Megna Michael R sold $383.2K2026-02-09 · Ragosa Mark sold $381.7K2026-09-03 · Megna Michael R sold $369.4K2026-04-06 · Patel Sanj K sold $364.0K2026-04-06 · Quart Barry D sold $345.1K2026-04-09 · Megna Michael R sold $309.3K2026-07-29 · Cole G Bradley sold $299.1K2026-03-02 · Paolini John F. sold $262.4K2026-09-03 · Megna Michael R filed to sell $369.4K2026-07-29 · Cole G Bradley filed to sell $299.1K2026-07-29 · Tessari Eben filed to sell $5.3M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $34.7M sold by insiders over 180 days, 157 funds added last quarter, $6.0M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Kiniksa Pharmaceuticals International, plc insiders sold a net $34.7M of stock across 153 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Megna Michael R
CHIEF ACCOUNTING OFFICER
SELL
2026-09-03
4,600.0
$369.4K
Cole G Bradley
Director
SELL
2026-07-29
3,673.0
$299.1K
Paolini John F.
CHIEF MEDICAL OFFICER
SELL
2026-05-01
37,327.0
$2.0M
Paolini John F.
CHIEF MEDICAL OFFICER
SELL
2026-05-01
21,097.0
$1.1M
Patel Sanj K
CHAIRMAN & CEO
SELL
2026-05-01
48,565.0
$2.6M
153 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 148 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
6,971,361.0 sh
$445.8M
Rubric Capital Management LP
3,999,800.0 sh
$255.8M
BAKER BROS. ADVISORS LP
2,834,643.0 sh
$181.3M
BlackRock, Inc.
2,739,615.0 sh
$175.2M
TANG CAPITAL MANAGEMENT LLC
2,259,889.0 sh
$144.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Megna Michael R
FILED 2026-09-03
$369.4K
Cole G Bradley
FILED 2026-07-29
$299.1K
Tessari Eben
FILED 2026-07-29
$5.3M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Oberweis Micro-Cap Fund
$14.7M POSITION · AS OF 2026-03-31
1.4%
JAMES MICRO CAP FUND
$332.7K POSITION · AS OF 2026-03-31
1.2%
Golden Eagle Dynamic Hypergrowth ETF
$297.8K POSITION · AS OF 2026-03-31
1.1%
Driehaus Micro Cap Growth Fund
$4.7M POSITION · AS OF 2026-03-31
1.0%
Clearwater Select Equity Fund
$2.9M POSITION · AS OF 2026-03-31
0.7%
Empower Small Cap Growth Fund
$1.5M POSITION · AS OF 2026-03-31
0.7%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 5 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 2
1 ACTIVE
1
Not applicable
1 ACTIVE
2
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Sanj K. Patel
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$10.8M
$28.4M
$3.5M
+133%
+25%
2024
$7.0M
$8.7M
$2.4M
+12%
-9%
2023
$5.3M
$6.8M
$1.8M
-1%
-8%
2022
$6.1M
$8.7M
$1.9M
-15%
-11%
2021
$6.6M
$579.5K
$1.7M
-33%
-1%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$677.6M$423.2M$270.3M$220.2M
OPERATING INCOME$77.2M$-45.6M$-25.2M$9.8M
NET INCOME$59.0M$-43.2M$14.1M$183.4M
EPS (DILUTED)0.75-0.600.202.60
OPERATING CASH FLOW$138.0M$25.7M$13.3M$5.8M
CASH$165.6M$183.6M$108.0M$122.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →